Nanomedicine News RSS Feed - Nanomedicine

Novel Method Utilizes Nanoparticles and UV Light to Isolate, Extract Contaminants

Novel Method Utilizes Nanoparticles and UV Light to Isolate, Extract Contaminants

Many human-made pollutants in the environment resist degradation through natural processes, and disrupt hormonal and other systems in mammals and other animals. Removing these toxic materials — which include pesticides and endocrine disruptors such as bisphenol A (BPA) — with existing methods is often expensive and time-consuming. [More]
MIT Scholars Engaged in Nanomaterials Study for Drug Delivery, Biofuel Catalysts

MIT Scholars Engaged in Nanomaterials Study for Drug Delivery, Biofuel Catalysts

From wet chemistry to computer simulations, this year's Materials Processing Center-Center for Materials Science and Engineering Summer Scholars are engaged in MIT research projects targeting stronger materials, more efficient drug delivery, and catalysts for biofuel production. [More]

NanoLock Signs Agreement to License its Nano-Polymer Additive that Protects Against Microbial Infection

NanoLock Ltd. entered this week into a license agreement with Hadasit Medical Research Services & Development Ltd. (Jerusalem, Israel), Hadassah Ein-Kerem Medical Center Jerusalem, and Yissum Research Development Com... [More]
Sticky-Flare Nanotechnology Reveals RNA Misregulation in Living Cells

Sticky-Flare Nanotechnology Reveals RNA Misregulation in Living Cells

RNA is a fundamental ingredient in all known forms of life -- so when RNA goes awry, a lot can go wrong. RNA misregulation plays a critical role in the development of many disorders, such as mental disability, autism and cancer. [More]
New Electron Microscopy Method Allows Nanoscale Studies of Breast Tumors in Their Native Liquid Environment

New Electron Microscopy Method Allows Nanoscale Studies of Breast Tumors in Their Native Liquid Environment

HER2 membrane proteins play a special role in certain types of breast cancer: amplified levels of HER2 drive unrestricted cell growth. HER2-tailored antibody-based therapeutics aim to prevent cancer cell growth. However, two-thirds of HER2 positive breast cancer patients develop resistance against HER2-targeting drugs. [More]
Nanoparticles May Help Tackle Acne

Nanoparticles May Help Tackle Acne

GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology. [More]
Remedium's Hemogrip Patch to Help Stop Bleeding Receives FDA Clearance

Remedium's Hemogrip Patch to Help Stop Bleeding Receives FDA Clearance

Remedium Technologies, a medical device company and University of Maryland spin-out advancing the standard of care for treating uncontrolled hemorrhage, today announces the 510(k) clearance of its Hemogrip™ Patch by the U.S. Food and Drug Administration (FDA). [More]
Magnetic Column Paired with Magnetic Nanoparticle Device May Help Increase use of Immunotherapy

Magnetic Column Paired with Magnetic Nanoparticle Device May Help Increase use of Immunotherapy

In recent years, researchers have hotly pursued immunotherapy, a promising form of treatment that relies on harnessing and training the body’s own immune system to better fight cancer and infection. [More]
ICAAC/ICC 2015: Matinas BioPharma to Present Preclinical Data on MAT2203 Lipid-Crystal Nano-Particle Delivered Amphotericin B Formulation

ICAAC/ICC 2015: Matinas BioPharma to Present Preclinical Data on MAT2203 Lipid-Crystal Nano-Particle Delivered Amphotericin B Formulation

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical data on its two lead anti-infective product candidates, MAT2203 and MAT2501, at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific meeting Sept. 17 - 21 in San Diego. [More]
Enrollment Initiated in Celator CPX-351 Phase 2 Clinical Study for Newly Diagnosed Acute Myeloid Leukemia

Enrollment Initiated in Celator CPX-351 Phase 2 Clinical Study for Newly Diagnosed Acute Myeloid Leukemia

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that patients have been enrolled in an investigator-initiated Phase 2 clinical study evaluating CPX-351 (cyatarabine:daunorubicin) Liposome Injection as a treatment for patients with newly diagnosed Acute Myeloid Leukemia (AML) at high risk for induction treatment mortality. [More]